Abbott’s State-of-the-Art Manufacturing Facility for Cardiac Devices in Penang - MIDA | Malaysian Investment Development Authority
contrastBtngrayscaleBtn oku-icon


plusBtn crossBtn minusBtn


This site
is mobile


Abbott’s State-of-the-Art Manufacturing Facility for Cardiac Devices in Penang

>Why Malaysia Series>Abbott’s State-of-the-Art Manufacturing Facility for Cardiac Devices in Penang

Abbott’s State-of-the-Art Manufacturing Facility for Cardiac Devices in Penang

Headquartered in Chicago, Abbott is a global healthcare leader dedicated to enhancing people’s lives throughout their entire lifespan. Abbott’s portfolio of life-changing technologies covers a wide spectrum of healthcare domains, with leading businesses and products for diagnostics, medical devices and Nutritional and Branded Generic Medicine. With a workforce of 115,000 professionals, they cater to individuals in over 160 nations.


At Abbott, they are not only creating the future of healthcare through the life-changing technologies and products, but they also swiftly detect medical requirements, provide treatment for ailments and facilitate individuals in returning to their cherished activities.

Abbott’s Penang presence

Established in 2009, Abbott’s Penang manufacturing site produce implantable heart devices for cardiac rhythm management. Good location that allows for ease of movement for goods and a dynamic skilled workforce have made Malaysia a choice for Abbott.


The Penang facility is a Class III medical devices manufacturer, and it is Abbott’s only manufacturing site for pacing devices in Asia. The facility accommodates a workforce of a thousand-plus employees who are committed in producing the highest quality of medical devices. They are also adhering to rigorous manufacturing practices and uphold a quality policy encapsulated in the phrase: BUILT AS IF INTENDED FOR MY FAMILY.


Located in Bayan Lepas, this Abbott site manufactures a variety of pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors and leads as well as printed circuit boards for the pacemakers and implantable cardioverter defibrillators catering to domestic and global demands.


These devices are used to treat and monitor the heart inside an individual’s body and they are expected to stay within the body for several years. As a Class III medical devices manufacturer, Abbott places their utmost priority in assuring the quality of their life-changing technology products, as they must operate within a patient’s body for a significant duration. All products undergo stringent testing to ensure reliability and minimise any potential issues.


In addition, the Penang site is also certified by regulatory inspection bodies from TUV, FDA (United States), SIRIM (Malaysia), CCC (China), TGA (Australia), ANVISA (Brazil), PMDA (Japan), MH RB (Belarus) & MH RK (Kazakhstan).

2030 Sustainability Plan: Evolving to Meet a Changing World's Needs

In order to create a stronger and healthier world, relying solely on cutting-edge innovations is insufficient. Abbott’s 2030 Sustainability Plan centers on incorporating accessibility and affordability for its life-changing technologies and products. Their goal is to improve the lives of more than 3 billion people by decade’s end – reaching 1 billion more than they do today, each year.


To align with the sustainability goal, the Penang site has implemented systems that reduces carbon footprints such as waste management, water and energy conservation. It is currently in the process of implementing zero landfill waste, solar panels and electric vehicles chargers that enables the reduction of its operational cost and CO2 emission which will contribute to Abbott’s 2030 sustainability goal.


Abbott’s continuous dedication and commitment has keep the company fostering their growth and success.